Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Sickle Cell Disease Treatment Market
Sickle Cell Disease Treatment Market Size
- Report ID: GMI5697
- Published Date: May 2023
- Report Format: PDF
Sickle Cell Disease Treatment Market Size
Sickle Cell Disease Treatment Market size surpassed USD 2.38 billion in 2022 and is anticipated to exhibit lucrative CAGR of around 12.6% between 2023 and 2032. The growth is attributed to factors such as the growing prevalence of sickle cell diseases, increasing R&D activities regarding sickle cell disease treatment, and increasing healthcare expenditure and government initiatives.
Sickle cell disease is the most common inherited red blood cell disorder. It affects the oxygen-carrying protein haemoglobin, which is present in the blood. People with sickle cell disease inherit two faulty haemoglobin genes, known as haemoglobin S, from their parents. Usually, the red blood cells are round and flexible for easy passage through blood vessels. In the case of sickle cell disease, the red blood cells change their shape to resemble a crescent moon or sickle. These sickle cells become sticky and rigid and cause slow blood flow or may block the blood flow.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Sickle Cell Disease Treatment Market Size in 2022: | USD 2.38 billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 12.6% |
| 2032 Value Projection: | USD 7.79 billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 190 |
| Tables, Charts & Figures: | 338 |
| Segments covered: | Treatment modality, Disease type, End-user, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
The management of sickle cell disease aims to avoid pain episodes, relieve the symptoms associated with the disease, and prevent complications. The treatment includes blood transfusions, medications, and bone marrow transplants.
Frequently Asked Questions (FAQ) :
Sickle Cell Disease Treatment Market Scope
